Serum neurofilament light chain - A potential biomarker for polyneuropathy in type 2 diabetes?
Diabetes Res Clin Pract
; 205: 110988, 2023 Nov.
Article
in En
| MEDLINE
| ID: mdl-38349953
ABSTRACT
AIMS:
To investigate the relationship between neurofilament light chain (NfL) and the presence and severity of diabetic polyneuropathy (DPN).METHODS:
We performed cross-sectional analysis of data from 178 participants of the ADDITION-Denmark cohort of people with screen-detected type 2 diabetes and 32 healthy controls. Biobank serum samples were analyzed for NfL using single-molecule array. DPN was defined by Toronto criteria for confirmed DPN. Original and axonal nerve conduction study (NCS) sum z-scores were used as indicators of the severity of DPN and peripheral nerve damage.RESULTS:
39 (21.9%) participants had DPN. Serum NfL (s-NfL) was significantly higher in participants with DPN (18.8 ng/L [IQR 14.4; 27.9]) than in participants without DPN (15.4 ng/L [IQR 11.7; 20.1]). There were no unadjusted s-NfL differences between controls (17.6 ng/L [IQR 12.7; 19.8]) and participants with or without DPN. Higher original and axonal NCS sum z-scores were associated with 10% higher s-NfL (10.2 and 12.1% [95% CI's 4.0; 16.8 and 6.6; 17.9] per 1 SD). The AUC of s-NfL for DPN was 0.63 (95% CI 0.52; 0.73).CONCLUSIONS:
S-NfL is unlikely to be a reliable biomarker for the presence of DPN. S-NfL is however associated tothe severity of the nerve damage underlying DPN.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Polyneuropathies
/
Peripheral Nervous System Diseases
/
Diabetes Mellitus, Type 2
Type of study:
Diagnostic_studies
/
Etiology_studies
/
Observational_studies
/
Prevalence_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Diabetes Res Clin Pract
/
Diabetes research and clinical practice (Online)
Journal subject:
ENDOCRINOLOGIA
Year:
2023
Document type:
Article
Country of publication:
Irlanda